Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC

This investigator-initiated, open-label, prospective Phase II clinical trial, planned to take place across multiple centers in China. We design this trial to evaluate the safety and efficacy of lorlatinib plus sacituzumab tirumotecan based on peripheral blood ctDNA as first-line treatment for ALK fusion NSCLC.

NCT Number	NCT07750704
Lead Sponsor	Guangdong Association of Clinical Trials
Conditions	ALK Positive Non-small Cell Lung Cancer
Enrollment	153 participants
Start Date	2026-09
Primary Completion	2029-09 (estimated)
Study Completion	2030-03 (estimated)
Updated on ClinicalTrials.gov	2026-08-06